Revefenacin
FDA-approved product (solution, inhalation), marketed as Yupelri.
- Registered studies
- 20
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Airway obstruction
- Chronic obstructive pulmonary disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Anticholinergics
- FDA pharmacologic class
- Anticholinergic FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli47.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae28.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis55.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
20registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Revefenacin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)
NCT07721922 · start 2026-09-01
Registered record
- Registry ID
- NCT07721922
- Conditions
- COPD Exacerbation
- Interventions
- Revefenacin; formoterol fumarate; Placebo (Sterile Normal Saline); Albuterol sulfate; Ipratropium Bromide
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Not yet recruiting
- Start
- 2026-09-01
- Completion
- 2028-09-01
- Enrolment
- 280
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCOPD ExacerbationInterventionRevefenacin; formoterol fumarate; Placebo (Sterile Normal Saline); Albuterol sulfate +1 morePhasePhase 4Registry statusNot yet recruitingCompare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators
NCT07133880 · start 2023-12-05
Registered record
- Registry ID
- NCT07133880
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease)
- Interventions
- umeclidinium 62.5 µg and vilanterol 25 µg; Revefenacin 175 µg, Formoterol 20 µg; Placebo ( Revefenacin and Formoterol ); Placebo DPI
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Recruiting
- Start
- 2023-12-05
- Completion
- 2026-12-01
- Enrolment
- 72
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCOPD (Chronic Obstructive Pulmonary Disease)Interventionumeclidinium 62.5 µg and vilanterol 25 µg; Revefenacin 175 µg, Formoterol 20 µg; Placebo ( Revefenacin and Formoterol ); Placebo DPIPhasePhase 4Registry statusRecruitingPhase 4 COPD and Suboptimal Inspiratory Flow Rate
NCT05165485 · start 2022-01-07
Registered record
- Registry ID
- NCT05165485
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Revefenacin; Tiotropium; Revefenacin Placebo; Tiotropium Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2022-01-07
- Completion
- 2023-11-20
- Enrolment
- 404
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Obstructive Pulmonary DiseaseInterventionRevefenacin; Tiotropium; Revefenacin Placebo; Tiotropium PlaceboPhasePhase 4Registry statusCompletedRevefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)
NCT05046795 · start 2021-11-10
Registered record
- Registry ID
- NCT05046795
- Conditions
- COPD
- Interventions
- Revefenacin 175 mcg in 3 ML Inhalation Solution; Placebo inhalation solution QD
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2021-11-10
- Completion
- 2023-07-26
- Enrolment
- 258
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCOPDInterventionRevefenacin 175 mcg in 3 ML Inhalation Solution; Placebo inhalation solution QDPhasePhase 3Registry statusCompletedFasting Bioavailability Study of Mylan's Revefenacin Inhalation Solution
NCT05207111 · start 2021-09-23
Registered record
- Registry ID
- NCT05207111
- Conditions
- Healthy Volunteers Bioavailability Study
- Interventions
- Revefenacin Inhalation Solution
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2021-09-23
- Completion
- 2021-09-30
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy Volunteers Bioavailability StudyInterventionRevefenacin Inhalation SolutionPhasePhase 1Registry statusCompletedFeasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD
NCT04655170 · start 2020-12-09
Registered record
- Registry ID
- NCT04655170
- Conditions
- COPD Exacerbation
- Interventions
- Revefenacin (YUPELRI) & Formoterol (Perforomist); Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2020-12-09
- Completion
- 2023-06-01
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCOPD ExacerbationInterventionRevefenacin (YUPELRI) & Formoterol (Perforomist); Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)PhasePhase 4Registry statusCompletedRevefenacin in Acute Respiratory Insufficiency in COPD
NCT04315558 · start 2020-11-01
Registered record
- Registry ID
- NCT04315558
- Conditions
- COPD; Acute Respiratory Failure
- Interventions
- Revefenacin Inhalation Solution [Yupelri]; Ipratropium Bromide
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2020-11-01
- Completion
- 2025-01-01
- Enrolment
- 21
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCOPD; Acute Respiratory FailureInterventionRevefenacin Inhalation Solution [Yupelri]; Ipratropium BromidePhasePhase 2Registry statusCompletedA 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
NCT03573817 · start 2018-05-31
Registered record
- Registry ID
- NCT03573817
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Revefenacin; Placebo; Formoterol
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2018-05-31
- Completion
- 2018-09-25
- Enrolment
- 122
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Obstructive Pulmonary Disease (COPD)InterventionRevefenacin; Placebo; FormoterolPhasePhase 3Registry statusCompletedRevefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
NCT03095456 · start 2017-03-27
Registered record
- Registry ID
- NCT03095456
- Conditions
- Chronic Obstructive Pulmonary Disease, COPD; Low Peak Inspiratory Flow Rate (PIFR)
- Interventions
- Revefenacin; Spiriva Handihaler®; Placebo for Revefenacin; Placebo for Spiriva Handihaler®
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2017-03-27
- Completion
- 2017-11-25
- Enrolment
- 207
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Obstructive Pulmonary Disease, COPD; Low Peak Inspiratory Flow Rate (PIFR)InterventionRevefenacin; Spiriva Handihaler®; Placebo for Revefenacin; Placebo for Spiriva Handihaler®PhasePhase 3Registry statusCompletedThorough QT (TQT) Study of TD-4208 in Healthy Subjects
NCT02820311 · start 2016-05
Registered record
- Registry ID
- NCT02820311
- Conditions
- Cardiac Repolarization in Healthy Subjects
- Interventions
- TD-4208 175 mcg; TD-4208 700 mcg; Placebo for TD-4208; Moxifloxacin 400 mg
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2016-05
- Completion
- 2016-07
- Enrolment
- 48
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCardiac Repolarization in Healthy SubjectsInterventionTD-4208 175 mcg; TD-4208 700 mcg; Placebo for TD-4208; Moxifloxacin 400 mgPhasePhase 1Registry statusCompletedPharmacokinetics of TD-4208 in Patients With Severe Renal Impairment
NCT02578082 · start 2015-12
Registered record
- Registry ID
- NCT02578082
- Conditions
- Renal Impairment
- Interventions
- TD-4208
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2015-12
- Completion
- 2016-05
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRenal ImpairmentInterventionTD-4208PhasePhase 1Registry statusCompletedPharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment
NCT02581592 · start 2015-11
Registered record
- Registry ID
- NCT02581592
- Conditions
- Hepatic Impairment
- Interventions
- TD-4208
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2015-11
- Completion
- 2016-04
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatic ImpairmentInterventionTD-4208PhasePhase 1Registry statusCompletedEfficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
NCT02459080 · start 2015-09
Registered record
- Registry ID
- NCT02459080
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- TD-4208; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2015-09
- Completion
- 2016-09
- Enrolment
- 619
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Obstructive Pulmonary Disease (COPD)InterventionTD-4208; PlaceboPhasePhase 3Registry statusCompletedEfficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
NCT02512510 · start 2015-09
Registered record
- Registry ID
- NCT02512510
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- TD-4208; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2015-09
- Completion
- 2016-09
- Enrolment
- 611
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Obstructive Pulmonary Disease (COPD)InterventionTD-4208; PlaceboPhasePhase 3Registry statusCompletedA 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
NCT02518139 · start 2015-09
Registered record
- Registry ID
- NCT02518139
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- TD-4208; Tiotropium
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2015-09
- Completion
- 2017-06
- Enrolment
- 1,060
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Obstructive Pulmonary Disease (COPD)InterventionTD-4208; TiotropiumPhasePhase 3Registry statusCompleted